Vaccines, Pneumococcal Conjugate Vaccine
9
0
0
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
78%
7 trials in Phase 3/4
67%
6 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (9)
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
Study Evaluating Prevenar Immunogenicity in High Risk Children
Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children